OBJECTIVE: To assess the impact of a granular measure of SED on pancreatic surgical and cancer-related outcomes at a high-volume cancer center that employs a standardized clinic pathway. SUMMARY OF BACKGROUND DATA: Prior research has shown that low socioeconomic status leads to less treatment and worse outcomes for PDAC. However, these studies employed inconsistent definitions and categorizations of socioeconomic status, aggregated individual socioeconomic data using large geographic areas, and lacked detailed clinicopathologic variables. METHODS: We conducted a retrospective cohort study of 1552 PDAC patients between 2008 and 2015. Patients were stratified using the area deprivation index, a validated dataset that ranks census block groups based on SED. Multivariable models were used in the curative surgery cohort to predict the impact of SED on (1) grade 3/4 Clavien-Dindo complications, (2) initiation of adjuvant therapy, (3) completion of adjuvant therapy, and (4) overall survival. RESULTS: Patients from high SED neighborhoods constituted 29.9% of the cohort. Median overall survival was 28 months. The rate of Clavien-Dindo grade 3/4 complications was 14.2% and completion of adjuvant therapy was 65.6%. There was no evidence that SED impacted surgical evaluation, receipt of curative-intent surgery, postoperative complications, receipt of adjuvant therapy or overall survival. CONCLUSIONS: Although nearly one-quarter of curative-intent surgery patients were from high SED neighborhoods, this factor was not associated with measures of treatment quality or survival. These observations suggest that treatment at a high-volume cancer center employing a standardized clinical pathway may in part address socioeconomic disparities in pancreatic cancer.
OBJECTIVE: To assess the impact of a granular measure of SED on pancreatic surgical and cancer-related outcomes at a high-volume cancer center that employs a standardized clinic pathway. SUMMARY OF BACKGROUND DATA: Prior research has shown that low socioeconomic status leads to less treatment and worse outcomes for PDAC. However, these studies employed inconsistent definitions and categorizations of socioeconomic status, aggregated individual socioeconomic data using large geographic areas, and lacked detailed clinicopathologic variables. METHODS: We conducted a retrospective cohort study of 1552 PDAC patients between 2008 and 2015. Patients were stratified using the area deprivation index, a validated dataset that ranks census block groups based on SED. Multivariable models were used in the curative surgery cohort to predict the impact of SED on (1) grade 3/4 Clavien-Dindo complications, (2) initiation of adjuvant therapy, (3) completion of adjuvant therapy, and (4) overall survival. RESULTS: Patients from high SED neighborhoods constituted 29.9% of the cohort. Median overall survival was 28 months. The rate of Clavien-Dindo grade 3/4 complications was 14.2% and completion of adjuvant therapy was 65.6%. There was no evidence that SED impacted surgical evaluation, receipt of curative-intent surgery, postoperative complications, receipt of adjuvant therapy or overall survival. CONCLUSIONS: Although nearly one-quarter of curative-intent surgery patients were from high SED neighborhoods, this factor was not associated with measures of treatment quality or survival. These observations suggest that treatment at a high-volume cancer center employing a standardized clinical pathway may in part address socioeconomic disparities in pancreatic cancer.
Authors: Pierre A Clavien; Jeffrey Barkun; Michelle L de Oliveira; Jean Nicolas Vauthey; Daniel Dindo; Richard D Schulick; Eduardo de Santibañes; Juan Pekolj; Ksenija Slankamenac; Claudio Bassi; Rolf Graf; René Vonlanthen; Robert Padbury; John L Cameron; Masatoshi Makuuchi Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: Ryan Z Swan; David J Niemeyer; Ramanathan M Seshadri; Kyle J Thompson; Amanda Walters; John B Martinie; David Sindram; David A Iannitti Journal: Am Surg Date: 2014-06 Impact factor: 0.688
Authors: Omeed Moaven; Joshua S Richman; Sushanth Reddy; Thomas Wang; Martin J Heslin; Carlo M Contreras Journal: Am J Surg Date: 2018-12-10 Impact factor: 2.565
Authors: Amani M Nuru-Jeter; Elizabeth K Michaels; Marilyn D Thomas; Alexis N Reeves; Roland J Thorpe; Thomas A LaVeist Journal: Annu Rev Public Health Date: 2018-01-12 Impact factor: 21.981
Authors: Lindsay A Bliss; Catherine J Yang; Zeling Chau; Sing Chau Ng; David W McFadden; Tara S Kent; A James Moser; Mark P Callery; Jennifer F Tseng Journal: HPB (Oxford) Date: 2014-06-06 Impact factor: 3.647
Authors: Daniela Dias-Santos; Cristina R Ferrone; Hui Zheng; Keith D Lillemoe; Carlos Fernández-Del Castillo Journal: Surgery Date: 2015-02-20 Impact factor: 3.982
Authors: Michelle L DeOliveira; Jordan M Winter; Markus Schafer; Steven C Cunningham; John L Cameron; Charles J Yeo; Pierre-Alain Clavien Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Melissa M Murphy; Jessica P Simons; Joshua S Hill; Theodore P McDade; Sing Chau Ng; Giles F Whalen; Shimul A Shah; Lynn H Harrison; Jennifer F Tseng Journal: Cancer Date: 2009-09-01 Impact factor: 6.860
Authors: Brent T Xia; David A Habib; Vikrom K Dhar; Nick C Levinsky; Young Kim; Dennis J Hanseman; Jeffrey M Sutton; Gregory C Wilson; Milton Smith; Kyuran Ann Choe; Jeffrey J Sussman; Syed A Ahmad; Daniel E Abbott Journal: Ann Surg Oncol Date: 2016-07-26 Impact factor: 5.344
Authors: Federico M Ghirimoldi; Susanne Schmidt; Richard C Simon; Chen-Pin Wang; Zhu Wang; Bradley B Brimhall; Paul Damien; Eric E Moffett; Laura S Manuel; Zaheer U Sarwar; Paula K Shireman Journal: J Gastrointest Surg Date: 2020-09-08 Impact factor: 3.452
Authors: Natalie Liu; Manasa Venkatesh; Bret M Hanlon; Anna Muraveva; Morgan K Johnson; Lawrence P Hanrahan; Luke M Funk Journal: Ann Surg Open Date: 2021-01-07
Authors: Daniel R Principe; Patrick W Underwood; Murray Korc; Jose G Trevino; Hidayatullah G Munshi; Ajay Rana Journal: Front Oncol Date: 2021-07-15 Impact factor: 6.244